PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

ClinicalTrials.gov ID: NCT00340704

Public ClinicalTrials.gov record NCT00340704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.

Study identification

NCT ID: NCT00340704
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 143 participants

Conditions and interventions

Conditions

Bladder, Neurogenic

Interventions

tamsulosin hydrochloride Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 16 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2006 (Type not available)
Primary completion: Jun 2009 (Actual)
Completion: Jun 2009 (Actual)
Last update posted: Feb 17, 2016

2006 – 2009

United States locations

U.S. sites: 19
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35233	—
Not listed	Los Angeles	California	90027	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Tampa	Florida	33614	—
Not listed	Springfield	Illinois	62702	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Shreveport	Louisiana	71106	—
Not listed	St Louis	Missouri	63110	—
Not listed	Buffalo	New York	14222	—
Not listed	Lake Success	New York	11042	—
Not listed	Tarrytown	New York	10591	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Akron	Ohio	44308	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Dallas	Texas	75235	—
Not listed	Houston	Texas	77030	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00340704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 17, 2016 · Synced Oct 29, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00340704 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →